Olaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor that is approved in the United States for patients with advanced breast cancer and advanced ovarian cancer. For patients receiving treatment for advanced cancer, fatigue and neuropathy―the latter in particular for those receiving platinum and/or taxanes―are among the most commonly reported adverse events.1 In this study, Ruiz-Schutz and colleagues performed a systematic literature review and meta-analysis of randomized controlled trials to characterize the risk for fatigue and neuropathy associated with the use of olaparib.

Nine studies representing 2074 patients with advanced ovarian, gastric, prostate, lung, or breast cancer were included in this analysis, with 908 (43.7%) patients receiving placebo/control treatments and 1166 (56.2%) receiving olaparib alone or in association with other active cancer treatments. Olaparib use was associated with increases in both all-grade fatigue (relative risk [RR], 1.24; 95% confidence interval [CI], 1.10-1.39) and high fatigue (hazard ratio [HR], 1.55; 95% CI, 1.14-2.09), as well as increases in high-grade fatigue (HR, 1.71; 95% CI, 1.06-2.77).

These results suggest that olaparib treatment is associated with an increased risk of fatigue. Given that fatigue is a very common treatment-related adverse event that can impair patients’ quality of life, it is important to identify it early and manage it accordingly to optimize overall treatment.

Reference

  1. Ruiz-Schutz, et al. ESMO 2018. Abstract 982P.
Related Items
A Phase 1b and Randomized Phase 2 Trial of Pazopanib with or Without Fosbretabulin in Advanced Recurrent Ovarian Cancer
Conference Correspondent  published on October 22, 2018 in ESMO 2018
The Efficacy of Apatinib Treatment for Advanced Ovarian Cancer After Second-Line Chemotherapy Failure
Conference Correspondent  published on October 22, 2018 in ESMO 2018
Oregovomab and Nivolumab as a Combinatorial Immunotherapy Strategy for Recurrent Epithelial Ovarian Cancer
Conference Correspondent  published on October 22, 2018 in ESMO 2018
Maintenance Olaparib Following Platinum-Based Chemotherapy in Newly Diagnosed Patients with Advanced Ovarian Cancer and a BRCA1/2 Mutation: Results from the Phase 3 SOLO1 Trial
Conference Correspondent  published on October 21, 2018 in ESMO 2018
A Phase 2 Trial of Combination Nivolumab and Bevacizumab in Recurrent Ovarian Cancer
Conference Correspondent  published on October 21, 2018 in ESMO 2018
Association of PD-L1 Expression with Clinical Response to Pembrolizumab in Patients with Advanced Recurrent Ovarian Cancer
Conference Correspondent  published on October 21, 2018 in ESMO 2018
A Phase 1/2 Study of Chemo-Immunotherapy with Durvalumab and Pegylated Liposomal Doxorubicin (PLD) in Platinum-Resistant Recurrent Ovarian Cancer
Conference Correspondent  published on October 20, 2018 in ESMO 2018
Meta-Analysis of PARP-Inhibitor–Associated Gastrointestinal and Hepatic Toxicities
Conference Correspondent  published on October 20, 2018 in ESMO 2018
Clinical Characteristics of Ovarian Cancer Relapse in BRCA1/2 Germ-Line Mutation Carriers and Noncarriers
Conference Correspondent  published on October 20, 2018 in ESMO 2018
A Phase 2 Study of Durvalumab, a PD-L1 Inhibitor, and Olaparib in Recurrent Ovarian Cancer
Conference Correspondent  published on October 20, 2018 in ESMO 2018
Last modified: October 22, 2018